Skip to main content
Clinical Trials/JPRN-UMIN000010291
JPRN-UMIN000010291
Recruiting
Phase 2

Efficacy of transcatheter arterial chemoembolization (TACE) with miriplatin for multiple hepatocellular carcinoma refractory or inappropriate to conventional TACE - Efficacy of transcatheter arterial chemoembolization (TACE) with miriplatin for multiple hepatocellular carcinoma refractory or inappropriate to conventional TACE

Department of Surgery, Graduate School of Medicine Kyoto University0 sites20 target enrollmentApril 1, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Multiple hepatocellular carcinoma
Sponsor
Department of Surgery, Graduate School of Medicine Kyoto University
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2013
End Date
March 31, 2016
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Surgery, Graduate School of Medicine Kyoto University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with another active cancer 2\) Patients with extrahepatic metastasis 3\) Patients with prior surgical reconstruction of the biliary tract or prior endoscopic treatment of ampulla of vater 4\) Patients with clinically significant refractory ascites or pleural effusion 5\) Patients with hepatic encephalopathy 6\) Patients with severe co\-morbidity such as cardiac failure and renal failure 7\) Patients with a medical history of severe hypersensitivity 8\) Patients who are pregnant, lactating or are suspected to be pregnant. 9\) Patients who are concluded to be inappropriate to participate in this study by their physicians

Outcomes

Primary Outcomes

Not specified

Similar Trials